Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.

Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Ahmed I, Piper T, Salunga R, Brachtel EF, Pirrie SJ, Schnabel CA, Rea DW.

Ann Oncol. 2019 Nov 1;30(11):1776-1783. doi: 10.1093/annonc/mdz289.

2.

Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.

Jerevall PL, Brock J, Palazzo J, Wieczorek T, Misialek M, Guidi AJ, Wu Y, Erlander MG, Zhang Y, Schnabel CA, Goss PE, Horick N, Sgroi DC.

Breast Cancer Res Treat. 2019 Jan;173(2):375-383. doi: 10.1007/s10549-018-5013-6. Epub 2018 Oct 22.

PMID:
30350269
3.

A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes.

Zhang Y, Schroeder BE, Jerevall PL, Ly A, Nolan H, Schnabel CA, Sgroi DC.

Clin Cancer Res. 2017 Dec 1;23(23):7217-7224. doi: 10.1158/1078-0432.CCR-17-1688. Epub 2017 Sep 22.

4.

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer.

Schroeder B, Zhang Y, Stål O, Fornander T, Brufsky A, Sgroi DC, Schnabel CA.

NPJ Breast Cancer. 2017 Aug 3;3:28. doi: 10.1038/s41523-017-0037-3. eCollection 2017.

5.

Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma.

Overman MJ, Soifer HS, Schueneman AJ, Ensor J Jr, Adsay V, Saka B, Neishaboori N, Wolff RA, Wang H, Schnabel CA, Varadhachary G.

BMC Cancer. 2016 Aug 22;16:668. doi: 10.1186/s12885-016-2677-3.

6.

Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.

Sestak I, Zhang Y, Schroeder BE, Schnabel CA, Dowsett M, Cuzick J, Sgroi D.

Clin Cancer Res. 2016 Oct 15;22(20):5043-5048. Epub 2016 Jun 1.

7.

Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.

Chapman JA, Sgroi DC, Goss PE, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Badovinac-Crnjevic T, Shepherd LE, Pollak MN.

Breast Cancer Res Treat. 2016 May;157(1):101-8. doi: 10.1007/s10549-016-3806-z. Epub 2016 Apr 26.

PMID:
27116182
8.

Molecular classification of cancer with the 92-gene assay in cytology and limited tissue samples.

Brachtel EF, Operaña TN, Sullivan PS, Kerr SE, Cherkis KA, Schroeder BE, Dry SM, Schnabel CA.

Oncotarget. 2016 May 10;7(19):27220-31. doi: 10.18632/oncotarget.8449.

9.

Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.

Sgroi DC, Chapman JA, Badovinac-Crnjevic T, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Shepherd LE, Goss PE, Pollak M.

Breast Cancer Res. 2016 Jan 4;18(1):1. doi: 10.1186/s13058-015-0660-6.

10.

Health economic analysis of Breast Cancer Index in patients with ER+, LN- breast cancer.

Gustavsen G, Schroeder B, Kennedy P, Pothier KC, Erlander MG, Schnabel CA, Ali H.

Am J Manag Care. 2014 Aug 1;20(8):e302-10.

11.

Cost effectiveness of a 92-gene assay for the diagnosis of metastatic cancer.

Bentley TG, Schroeder BE, Schnabel CA, Erlander MG, Hsiao WC, Ortendahl JD, Broder MS.

J Med Econ. 2014 Aug;17(8):527-37. doi: 10.3111/13696998.2014.909817. Epub 2014 May 14.

PMID:
24689556
12.

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.

Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M.

Lancet Oncol. 2013 Oct;14(11):1067-1076. doi: 10.1016/S1470-2045(13)70387-5. Epub 2013 Sep 12. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

13.

A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors.

Kerr SE, Schnabel CA, Sullivan PS, Zhang Y, Huang VJ, Erlander MG, Brachtel EF, Dry SM.

Mod Pathol. 2014 Jan;27(1):44-54. doi: 10.1038/modpathol.2013.105. Epub 2013 Jul 12.

14.

Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.

Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y, Schnabel CA, Erlander MG, Ingle JN, Porter P, Muss HB, Pritchard KI, Tu D, Rimm DL, Goss PE.

J Natl Cancer Inst. 2013 Jul 17;105(14):1036-42. doi: 10.1093/jnci/djt146. Epub 2013 Jun 28.

15.

Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.

Zhang Y, Schnabel CA, Schroeder BE, Jerevall PL, Jankowitz RC, Fornander T, Stål O, Brufsky AM, Sgroi D, Erlander MG.

Clin Cancer Res. 2013 Aug 1;19(15):4196-205. doi: 10.1158/1078-0432.CCR-13-0804. Epub 2013 Jun 11.

16.

Development and validation of a 32-gene prognostic index for prostate cancer progression.

Wu CL, Schroeder BE, Ma XJ, Cutie CJ, Wu S, Salunga R, Zhang Y, Kattan MW, Schnabel CA, Erlander MG, McDougal WS.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6121-6. doi: 10.1073/pnas.1215870110. Epub 2013 Mar 26.

17.

Gene expression-based diagnostics for molecular cancer classification of difficult to diagnose tumors.

Schnabel CA, Erlander MG.

Expert Opin Med Diagn. 2012 Sep;6(5):407-19. doi: 10.1517/17530059.2012.704363. Epub 2012 Jul 10.

PMID:
23480806
18.

Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors.

Weiss LM, Chu P, Schroeder BE, Singh V, Zhang Y, Erlander MG, Schnabel CA.

J Mol Diagn. 2013 Mar;15(2):263-9. doi: 10.1016/j.jmoldx.2012.10.001. Epub 2012 Dec 31.

19.

Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier.

Kerr SE, Schnabel CA, Sullivan PS, Zhang Y, Singh V, Carey B, Erlander MG, Highsmith WE, Dry SM, Brachtel EF.

Clin Cancer Res. 2012 Jul 15;18(14):3952-60. doi: 10.1158/1078-0432.CCR-12-0920. Epub 2012 May 30.

20.

Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy.

Mathieu MC, Mazouni C, Kesty NC, Zhang Y, Scott V, Passeron J, Arnedos M, Schnabel CA, Delaloge S, Erlander MG, André F.

Ann Oncol. 2012 Aug;23(8):2046-52. doi: 10.1093/annonc/mdr550. Epub 2011 Nov 22.

21.

A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.

Hainsworth JD, Schnabel CA, Erlander MG, Haines DW 3rd, Greco FA.

Clin Colorectal Cancer. 2012 Jun;11(2):112-8. doi: 10.1016/j.clcc.2011.08.001. Epub 2011 Oct 14.

PMID:
22000811
22.

Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification.

Erlander MG, Ma XJ, Kesty NC, Bao L, Salunga R, Schnabel CA.

J Mol Diagn. 2011 Sep;13(5):493-503. doi: 10.1016/j.jmoldx.2011.04.004. Epub 2011 Jun 25.

23.

Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.

Schnabel CA, Wintle M, Kolterman O.

Vasc Health Risk Manag. 2006;2(1):69-77. Review.

24.

Immunogenicity of xenopeptide hormone therapies.

Schnabel CA, Fineberg SE, Kim DD.

Peptides. 2006 Jul;27(7):1902-10. Epub 2006 Mar 3. Review.

PMID:
16517012
25.

Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.

Ceriello A, Piconi L, Quagliaro L, Wang Y, Schnabel CA, Ruggles JA, Gloster MA, Maggs DG, Weyer C.

Diabetes Care. 2005 Mar;28(3):632-7.

PMID:
15735200
26.

Time-of-flight optophoresis analysis of live whole cells in microfluidic channels.

Zhang H, Tu E, Hagen ND, Schnabel CA, Paliotti MJ, Hoo WS, Nguyen PM, Kohrumel JR, Butler WF, Chachisvillis M, Marchand PJ.

Biomed Microdevices. 2004 Mar;6(1):11-21.

PMID:
15307440
27.

Pbx1 is essential for adrenal development and urogenital differentiation.

Schnabel CA, Selleri L, Cleary ML.

Genesis. 2003 Nov;37(3):123-30.

PMID:
14595835
28.

Optical forces for noninvasive cellular analysis.

Wang MM, Schnabel CA, Chachisvilis M, Yang R, Paliotti MJ, Simons LA, McMullin L, Hagen N, Lykstad K, Tu E, Pestana LM, Sur S, Zhang H, Butler WF, Kariv I, Marchand PJ.

Appl Opt. 2003 Oct 1;42(28):5765-73.

PMID:
14528941
29.

Pbx1 regulates nephrogenesis and ureteric branching in the developing kidney.

Schnabel CA, Godin RE, Cleary ML.

Dev Biol. 2003 Feb 15;254(2):262-76.

30.

Expression of Pbx1b during mammalian organogenesis.

Schnabel CA, Selleri L, Jacobs Y, Warnke R, Cleary ML.

Mech Dev. 2001 Jan;100(1):131-5.

31.
32.
33.

CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity.

Kasper LH, Brindle PK, Schnabel CA, Pritchard CE, Cleary ML, van Deursen JM.

Mol Cell Biol. 1999 Jan;19(1):764-76.

34.

Supplemental Content

Loading ...
Support Center